Clinical trials: Overfed
Overweight, Obesity
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 6 (NCT03811574)
- Testing
- Semaglutide
- Where
- 28 sites in Japan, South Korea
- Volunteers
- 401 people
- Sponsor
- Novo Nordisk A/S
Binge Eating, Obesity
Feasibility of a Digital Therapeutic for Adults With Binge Eating and Obesity
The primary objective of this study is to test the feasibility of a digital therapeutic to address comorbid binge eating and obesity in adults.
- Trial name
- NCT06454123
- Testing
- OTX-401
- Volunteers
- 30 people
- Sponsor
- Oui Therapeutics, Inc.
Obesity and Overweight
A Study of IBI3046 in Participants With Overweight or Obesity
This study evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3046 in Chinese overweight or obese participants, comprising four phases: single ascending dose (SAD), multiple ascending dose (MAD)…
- Trial name
- NCT07809945
- Testing
- IBI3046
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight, Obesity
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities.
- Trial name
- NCT06023095
- Testing
- LY3502970
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Obesity
Study to Evaluate ARD-101 in Adults With Obesity
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.
- Trial name
- NCT05121441
- Testing
- ARD-101
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Aardvark Therapeutics, Inc.
Hypercholesterolemia, Cardiovascular Risk Factor
Effect of Totum-070 on Lipid Metabolism in Moderate Hypercholesterolemic Subjects
This clinical study aims to assess the efficacy of TOTUM-070, a mix of 5 plant extracts, on lipid metabolism in moderate hypercholesterolemic subjects.
- Conditions
- Hypercholesterolemia, Cardiovascular Risk Factor, Dyslipidemias, Overweight and Obesity
- Trial name
- HEART (NCT04760951)
- Testing
- TOTUM-070
- Where
- 4 sites in France, Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Overweight, Obesity
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
This is a randomized, investigator-and-participant-blind, placebo-controlled, fixed sequence, cross-over, Phase 1 study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of orally administered…
- Trial name
- NCT06982131
- Testing
- RO7795081, Rosuvastatin, Pitavastatin
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Obesity
Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects
This study aims to evaluate the safety, tolerability, pharmacokinetics, and food effect of a new investigational medicine called SCB0020160 in healthy adult men. This is the first time SCB0020160 will be administered to humans.
- Conditions
- Solid Tumor, Obesity, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT07682337
- Testing
- SCB0020160
- Where
- Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- SCBIO Inc.
Overweight and Obesity
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
The primary objective of this trial is to evaluate the pharmacokinetics of a single subcutaneous (SC) dose of AMG 133 in participants with various degrees of renal impairment compared to participants with normal renal function.
- Trial name
- NCT07429045
- Testing
- AMG 133
- Where
- 5 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Insulin Resistance, Obesity
Tea-beetroot-venous Occlusion Plethysmography
In the present study, muscle perfusion will be studied before and after an oral glucose challenge following a fasting period.
- Trial name
- NCT01746329
- Testing
- Tea, Beet root
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Obesity
Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans
The purpose of this study is to retrospectively and systematically review records of overweight and obese Medifast Weight Control Center (MWCC) members who have been assigned to the 5 \& 2 \& 2 Plan or the 4 \& 2 \& 1 Plan for…
- Trial name
- NCT02150837
- Testing
- 5 & 2 & 2 Plan, 4 & 2 & 1 Plan
- Where
- United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Medifast, Inc.
Crohn's Disease, Obesity or Overweight
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and…
- Trial name
- COMMIT-CD (NCT06937099)
- Testing
- Mirikizumab, Tirzepatide
- Where
- 183 sites in United States, Austria and 20 more
- Volunteers
- 290 people
- Sponsor
- Eli Lilly and Company
Obesity
A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112
1. Study Objective <Part 1> To evaluate the safety and pharmacokinetic/pharmacodynamic characteristics of HSG4112 after multiple oral administration in healthy female subjects.
- Trial name
- NCT04703764
- Testing
- HSG4112
- Where
- 2 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Glaceum
Obesity, Weight Loss
ReShape Vest™ for the Treatment of Obesity (Europe)
To assess the safety and effectiveness of the LGV in treating obese subjects with a BMI of 35 kg/m2 to 55 kg/m2 who have failed one or more conservative weight-reduction alternative(s), such as supervised diet, exercise, and…
- Trial name
- NCT03918564
- Testing
- Laparoscopic Gastric Vest (LGV)
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- ReShape Lifesciences
Type 2 Diabetes, Obesity
Study for Pre-Surgical Weight Loss in Type II Diabetes Patients
The purpose of this study is to determine whether the GI Sleeve is safe and effective in treating Type II diabetes patients
- Trial name
- NCT00791128
- Testing
- GI Liner
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Morphic Medical Inc.
Type 2 Diabetes, Overweight or Obesity
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT05814107
- Testing
- CT-996
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Carmot Australia First Pty Ltd
Obesity/Overweight
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study in adult obese/overweight subjects in China to evaluate the efficacy and safety of GZR18 Injection in the subjects.
- Trial name
- NCT06728124
- Testing
- GZR18
- Where
- China
- Volunteers
- 630 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity, Overweight
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without…
- Trial name
- Elecoglipron (NCT07775404)
- Testing
- Elecoglipron
- Where
- 49 sites in China, Hong Kong and 3 more
- Volunteers
- 351 people
- Sponsor
- AstraZeneca
Obesity
A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men
The study is testing a new study drug in healthy normal weight Japanese and Caucasian participants after a single dose. The aim of this study is to see if the new medicine is safe and how it works in the participants body.
- Trial name
- NCT06542536
- Testing
- Monlunabant
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
- Trial name
- NCT06885021
- Testing
- HDM1002 200mg, oral, once daily, 52 weeks, HDM1002 400mg, oral, once daily, 52 weeks
- Volunteers
- 780 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.